17 January 2020 - Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial and therapeutic expertise.
Dr. Howd has over 20 years’ experience in the life science sector. He has held various private and public company Executive and Board roles in the UK, EU and US, including Immunocore, Poseida Therapeutics, Viamet and Malin. As CEO of Malin, he led equity capital raises totalling EUR 430m and implemented the operational and strategic refinement and priority asset focus for the company.
Prior to this, Dr. Howd also held numerous investment and finance roles within global financial institutions. He received his PhD in Neuroscience from St. Thomas’s Hospital, University of London and undertook a postdoctoral fellowship at the National Institutes of Health, Bethesda Maryland.
Andrew Kay, Chairman, said: “We are delighted to welcome Adrian to our Board and I am certain he will provide Blueberry Therapeutics with solid counsel. He has a proven track record of working with fast growing companies, including those with dermatology and anti-infective focus”
“Adrian’s experience of senior Executive and Board roles and numerous investment and financing roles will help to drive the company forward and achieve our continued success.”
Adrian Howd, NED, said: “I am delighted to be joining Blueberry Therapeutics, a company with novel technology and a pipeline of drugs with clear pathways to commercialisation. I welcome the opportunity to work alongside Chairman Andrew Kay and a highly experienced Board and management team at this exciting time in the company’s evolution.”
About Blueberry Therapeutics Limited
Blueberry Therapeutics Ltd., incorporated in November 2011, is a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections. The company is using its state of the art nano-formulation technology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.
Blueberry Therapeutics combines expert in-house resources with selected outsource partners and collaborators to take projects through from preclinical research onto de-risked human clinical proof of concept and then on to the market.